



## Surmodics IVD Launches Breakthrough StabilBlock® Immunoassay Stabilizer

August 1, 2016

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Aug. 1, 2016-- Surmodics, Inc. (NASDAQ: SRDX), the global leader in chemical components for in vitro diagnostic (IVD) tests and microarrays, has announced the launch and immediate availability of StabilBlock®, its most advanced Immunoassay Stabilizer. StabilBlock Immunoassay Stabilizer is the best available reagent for reducing non-specific binding to boost immunoassay signal-to-noise ratios.

Surmodics offers a family of immunoassay stabilizers, which preserve the conformation and activity of dried proteins on a wide range of surfaces, keeping antibodies and antigens at peak performance for long durations. At the same time, the blocking mechanisms in these reagents reduce non-specific binding of interfering proteins to maximize assay sensitivity. With StabilBlock, StabilCoat® and StabilGuard® Immunoassay Stabilizers, the company now offers three options to assay developers with a combination of blocking efficacy and long-term dried stability that is unmatched in the industry.

"As part of our commitment to being the premier provider of IVD assay components to improve performance and manufacturability of immunoassays, we continue to advance our offerings to meet the needs of our customers," said Joe Stich, vice president and general manager of Surmodics IVD, the company's In Vitro Diagnostics business. "We recognize that each assay has its own blocking requirements and our expanded portfolio of Immunoassay Stabilizers will enable assay developers to achieve the best results for each application."

Surmodics IVD products immediately improve assay performance and manufacturability of assays by lowering backgrounds, increasing signal generation and providing longer shelf lives for immunoassay production. The addition of StabilBlock Immunoassay Stabilizer augments the company's leading portfolio of products, including:

- The StabilZyme® family provides unparalleled long-term stability of protein conjugates at working strength concentrations. Surmodics formulations for HRP conjugates, AP conjugates and general protein applications ensure that assay developers have a complete set of tools to address the labile nature of each protein of interest.
- BioFX® TMB substrate family outperforms competitors for low background, stability and sensitivity with a variety of kinetic rate substrates. The one-component formulations provide optimal signal generation and longer shelf lives.
- Assay Diluent (Protein-Free) normalizes the sample matrix and reduces interference to ensure that analyte-specific signal is generated within an assay system.

### About Surmodics, Inc.

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) tests and microarrays. Following two recent acquisitions of Creagh Medical and NorMedix, the company is executing a key growth strategy for its medical device business by expanding to offer total intravascular product solutions to its medical device customers. The combination of proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities, enables Surmodics to significantly increase the value it offers with highly differentiated intravascular solutions designed and engineered to meet the most demanding requirements.

With this focus on offering total product solutions, Surmodics' mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information about the company, visit [www.surmodics.com](http://www.surmodics.com). The content of Surmodics' website is not part of this press release or part of any filings that the company makes with the SEC.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160801005190/en/>

Source: Surmodics, Inc.

Surmodics, Inc.

Andy LaFrence, 952-500-7000

Vice President of Finance and Chief Financial Officer